UK trial assessing AZ’ AZD1775 in head and neck cancer
AstraZeneca | November 27, 2017
A clinical trial testing AstraZeneca’s experimental drug AZD1775, an inhibitor of the cell cycle regulating protein WEE1, in patients with head and neck cancer has now launched in the UK.